MCID: HYP056
MIFTS: 65

Hypoglycemia

Categories: Blood diseases, Endocrine diseases, Genetic diseases, Metabolic diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Hypoglycemia

MalaCards integrated aliases for Hypoglycemia:

Name: Hypoglycemia 11 75 28 53 5 41 43 14 71 33
Hypoglycaemia 11 14
Hypoglycaemic Disorder Nos 33
Spontaneous Hypoglycaemia 33
Nondiabetic Hypoglycaemia 33
Hypoglycaemic Syndrome 33
Hypoglycaemia Nos 33
Low Blood Sugar 33

Classifications:



External Ids:

Disease Ontology 11 DOID:9993
ICD9CM 34 251.2
MeSH 43 D007003
NCIt 49 C3126
SNOMED-CT 68 154691006
ICD10 31 E16.2
ICD11 33 1004695600
UMLS 71 C0020615

Summaries for Hypoglycemia

MedlinePlus: 41 Hypoglycemia means low blood glucose, or blood sugar. Your body needs glucose to have enough energy. After you eat, your blood absorbs glucose. If you eat more sugar than your body needs, your muscles, and liver store the extra. When your blood sugar begins to fall, a hormone tells your liver to release glucose. In most people, this raises blood sugar. If it doesn't, you have hypoglycemia, and your blood sugar can be dangerously low. Signs include : Hunger Shakiness Dizziness Confusion Difficulty speaking Feeling anxious or weak In people with diabetes, hypoglycemia is often a side effect of diabetes medicines. Eating or drinking something with carbohydrates can help. If it happens often, your health care provider may need to change your treatment plan. You can also have low blood sugar without having diabetes. Causes include certain medicines or diseases, hormone or enzyme deficiencies, and tumors. Laboratory tests can help find the cause. The kind of treatment depends on why you have low blood sugar. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary: Hypoglycemia, also known as hypoglycaemia, is related to hyperinsulinemic hypoglycemia, familial, 2 and hypoglycemia, leucine-induced, and has symptoms including sugar craving An important gene associated with Hypoglycemia is ABCC8 (ATP Binding Cassette Subfamily C Member 8), and among its related pathways/superpathways are Metabolism and PI3K-Akt signaling pathway. The drugs Pancrelipase and Insulin aspart have been mentioned in the context of this disorder. Affiliated tissues include liver, kidney and heart, and related phenotypes are homeostasis/metabolism and liver/biliary system

Disease Ontology: 11 A glucose metabolism disease that is characterized by abnormally low levels of blood glucose.

Wikipedia: 75 Hypoglycemia, also called low blood sugar, is a fall in blood sugar to levels below normal, typically... more...

Related Diseases for Hypoglycemia

Diseases related to Hypoglycemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1410)
# Related Disease Score Top Affiliating Genes
1 hyperinsulinemic hypoglycemia, familial, 2 33.6 KCNJ11 INS IGF2 ABCC8
2 hypoglycemia, leucine-induced 33.3 KCNJ11 HADH GLUD1 ABCC8
3 hyperinsulinemic hypoglycemia, familial, 7 33.2 SLC16A1 KCNJ11 HADH GLUD1 GCK ABCC8
4 hyperinsulinemic hypoglycemia, familial, 3 33.2 GCK ABCC8
5 hyperinsulinemic hypoglycemia, familial, 6 33.1 SLC16A1 KCNJ11 HADH GLUD1 GCK ABCC8
6 hyperinsulinemic hypoglycemia 33.1 SLC16A1 KCNJ11 INSR INS IGF2 HADH
7 hyperinsulinemic hypoglycemia, familial, 4 33.0 INSR HADH
8 carnitine palmitoyltransferase ii deficiency, infantile 32.8 SLC25A20 HADH CPT1A ACADVL ACADM
9 hirata disease 32.8 INS GCG
10 type 1 diabetes mellitus 32.6 INS IGF2 GCK GCG
11 carnitine palmitoyltransferase i deficiency 32.5 SLC25A20 HADH CPT1A ACADVL ACADM
12 carnitine-acylcarnitine translocase deficiency 32.5 SLC25A20 CPT1A ACADVL ACADM
13 fructose-1,6-bisphosphatase deficiency 32.5 HADH GCK G6PC1 FBP1 ABCC8
14 acyl-coa dehydrogenase, very long-chain, deficiency of 32.4 SLC25A20 HADH ACADVL ACADM ACADL
15 mitochondrial trifunctional protein deficiency 32.4 SLC25A20 HADH ACADVL ACADM
16 insulinoma 32.4 KCNJ11 INS IGF2 GCK GCG G6PC1
17 hyperinsulinism 32.4 SLC16A1 KCNJ11 INSR INS IGF2 HADH
18 carnitine deficiency, systemic primary 32.4 SLC25A20 HADH ACADVL ACADM
19 glycogen storage disease ia 32.3 INS GYS2 GCG G6PC1 FBP1 AGL
20 glycogen storage disease iii 32.3 GYS2 G6PC1 AGL
21 multiple acyl-coa dehydrogenase deficiency 32.3 SLC25A20 HADH ACADVL ACADM
22 acyl-coa dehydrogenase, medium-chain, deficiency of 32.2 SLC25A20 HADH ACADVL ACADM ACADL
23 glycogen storage disease vi 32.2 GYS2 G6PC1 AGL
24 beckwith-wiedemann syndrome 32.2 SLC16A1 KCNJ11 INS IGF2 HADH ABCC8
25 gestational diabetes 32.1 KCNJ11 INSR INS GCK GCG ABCC8
26 galactosemia i 32.1 HADH ACADVL ACADM
27 hyperglycemia 32.0 KCNJ11 INSR INS GCK GCG G6PC1
28 diabetes mellitus 32.0 KCNJ11 INSR INS IGF2 GCK GCG
29 donohue syndrome 31.9 INSR INS GCK
30 sheehan syndrome 31.9 INS CRH
31 monocarboxylate transporter 1 deficiency 31.9 SLC16A1 INS GLUD1
32 acyl-coa dehydrogenase, short-chain, deficiency of 31.9 HADH ACADVL ACADM
33 islet cell tumor 31.8 INS IGF2 GCG
34 type 2 diabetes mellitus 31.7 KCNJ11 INSR INS IGF2 GCK GCG
35 hypoglycemic coma 31.6 INS IGF2 GCG
36 lactic acidosis 31.5 INS GCG G6PC1 FBP1
37 diabetes mellitus, ketosis-prone 31.4 KCNJ11 INS GCG
38 glycogen storage disease 31.3 INS IGF2 GYS2 G6PC1 AGL
39 potter's syndrome 31.2 INS IGF2
40 prediabetes syndrome 31.2 KCNJ11 INSR INS GCK GCG ABCC8
41 insulin-like growth factor i 31.1 INSR INS IGF2
42 pituitary gland disease 31.1 INS GCG CRH
43 glucose intolerance 31.0 KCNJ11 INSR INS GCK GCG ABCC8
44 asphyxia neonatorum 31.0 SLC16A1 KCNJ11 INS HADH ABCC8
45 abdominal obesity-metabolic syndrome 1 31.0 INS GCK GCG G6PC1 ACADM
46 maturity-onset diabetes of the young 31.0 SLC16A1 KCNJ11 INSR INS IGF2 GCK
47 lipid metabolism disorder 31.0 INSR INS GCG G6PC1 CPT1A ACADVL
48 liver cirrhosis 31.0 INSR INS GCG AGL
49 maturity-onset diabetes of the young, type 1 30.9 KCNJ11 INS GCK ABCC8
50 factitious disorder 30.9 KCNJ11 INS GCK GCG ABCC8

Comorbidity relations with Hypoglycemia via Phenotypic Disease Network (PDN): (show all 31)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Alzheimer Disease, Familial, 1
Benign Essential Hypertension Bronchitis
Cerebral Atherosclerosis Chronic Kidney Disease
Decubitus Ulcer Deficiency Anemia
Diabetic Polyneuropathy Encephalopathy
Familial Atrial Fibrillation First-Degree Atrioventricular Block
Generalized Atherosclerosis Heart Disease
Hypertension, Essential Hypoglycemic Coma
Hypothyroidism Intermediate Coronary Syndrome
Iron Deficiency Anemia Kidney Disease
Microvascular Complications of Diabetes 1 Microvascular Complications of Diabetes 7
Mitral Valve Disease Peripheral Vascular Disease
Protein-Energy Malnutrition Respiratory Failure
Schizophreniform Disorder Sinoatrial Node Disease
Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Hypoglycemia:



Diseases related to Hypoglycemia

Symptoms & Phenotypes for Hypoglycemia

UMLS symptoms related to Hypoglycemia:


sugar craving

GenomeRNAi Phenotypes related to Hypoglycemia according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.18 ABCC8 ACADL ACADM ACADVL AGL CPT1A
2 no effect GR00402-S-2 10.18 ABCC8 AGL CPT1A CRH FBP1 G6PC1

MGI Mouse Phenotypes related to Hypoglycemia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.32 ABCC8 ACADL ACADM ACADVL AGL CPT1A
2 liver/biliary system MP:0005370 10.22 ACADL ACADM ACADVL AGL CRH G6PC1
3 renal/urinary system MP:0005367 10.2 ACADL AGL CRH G6PC1 GCG GCK
4 growth/size/body region MP:0005378 10.13 ABCC8 ACADVL AGL CRH G6PC1 GCG
5 muscle MP:0005369 10.03 ACADM ACADVL AGL GYS2 IGF2 INS
6 adipose tissue MP:0005375 9.97 ACADVL AGL CRH HADH INS INSR
7 endocrine/exocrine gland MP:0005379 9.9 ABCC8 CRH GCG GCK GLUD1 HADH
8 cardiovascular system MP:0005385 9.77 ABCC8 ACADL ACADM ACADVL AGL CPT1A
9 mortality/aging MP:0010768 9.47 ACADL ACADM ACADVL AGL CPT1A G6PC1

Drugs & Therapeutics for Hypoglycemia

Drugs for Hypoglycemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 249)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pancrelipase Approved, Investigational Phase 4 53608-75-6 8519
2
Insulin aspart Approved Phase 4 116094-23-6 16132418
3
Pramlintide Approved, Investigational Phase 4 151126-32-8 139600705 70691388
4
Acarbose Approved, Investigational Phase 4 56180-94-0 441184 444254
5
Zinc cation Approved, Experimental, Investigational Phase 4 7440-66-6, 23713-49-7 32051
6
Glyburide Approved Phase 4 10238-21-8 3488
7
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
8
Liraglutide Approved Phase 4 204656-20-2 44147092 16134956
9
Lixisenatide Approved Phase 4 320367-13-3 90472060 16139342
10
Gliclazide Approved Phase 4 21187-98-4 3475
11
Empagliflozin Approved Phase 4 864070-44-0 73151030 11949646
12
Verapamil Approved Phase 4 152-11-4, 52-53-9 2520
13
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1, 93107-08-5 2764
14
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
15
Ofloxacin Approved Phase 4 82419-36-1 4583
16
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
17
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
18
Diazoxide Approved Phase 4 364-98-7 3019
19
Insulin glargine Approved Phase 4 160337-95-1 118984454
20
Insulin detemir Approved Phase 4 169148-63-4 16137271
21
Gastric inhibitory polypeptide Investigational Phase 4 100040-31-1
22 Hypoglycemic Agents Phase 4
23 Insulin, Globin Zinc Phase 4
24
Insulin Phase 4
25 Pancreatin Phase 4
26 Antihypertensive Agents Phase 4
27 Vasodilator Agents Phase 4
28 Cardiac Glycosides Phase 4
29 Glycoside Hydrolase Inhibitors Phase 4
30 Cytochrome P-450 Enzyme Inhibitors Phase 4
31 calcium channel blockers Phase 4
32 Insulin degludec, insulin aspart drug combination Phase 4
33 Cathartics Phase 4
34 Laxatives Phase 4
35 (1-6)-alpha-glucomannan Phase 4
36 Manna Phase 4
37 Insulin aspart, insulin aspart protamine drug combination 30:70 Phase 4
38 Biphasic Insulins Phase 4
39 Insulin, Long-Acting Phase 4
40 Insulin, Isophane Phase 4
41 Isophane Insulin, Human Phase 4
42 Isophane insulin, beef Phase 4
43 Diuretics, Potassium Sparing Phase 4
44 diuretics Phase 4
45 Mineralocorticoids Phase 4
46 Mineralocorticoid Receptor Antagonists Phase 4
47 Betamethasone-17,21-dipropionate Phase 4
48
Betamethasone Valerate Phase 4 2152-44-5
49
Betamethasone sodium phosphate Phase 4
50
Betamethasone benzoate Phase 4

Interventional clinical trials:

(show top 50) (show all 584)
# Name Status NCT ID Phase Drugs
1 Glucose Control During Labour in Gestational Diabetes Mellitus With Insulin Treatment: Insulin-Glucose-Infusion Versus Observational Approach - Is There a Difference in Neonatal Hypoglycemia Rate? Unknown status NCT02590016 Phase 4 Insulin, Aspart
2 Pasireotide in the Treatment of Hypoglycemia Following Gastric Bypass Surgery Unknown status NCT03514576 Phase 4 Pasireotide 0.3 MG/ML
3 Treatment of Hypoglycemia With Glucagon Among Patients With Type 1 Diabetes Mellitus Unknown status NCT02232971 Phase 4 Glucagon
4 Do Sulphonylureas Preserve Cortical Function During Hypoglycaemia? Unknown status NCT00472875 Phase 4 Glibenclamide
5 Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery Completed NCT01841359 Phase 4 Pramlintide
6 NEONATAL HYPOGLYCEMIA and CONTINUOUS GLUCOSE MONITORING: A RANDOMIZED CONTROLLED TRIAL IN PRETERM INFANTS Completed NCT02583776 Phase 4
7 The Effect of Sitagliptin on Glucagon Counterregulation and Incretin Hormones During Mild Hypoglycemia in Elderly Patients With Metformin-treated Type 2 Diabetes Completed NCT02256189 Phase 4 Sitagliptin;Placebo
8 Treatment With Sitagliptin Phosphate in Patients With Reactive Hypoglycemia Secondary to Dysinsulinism. A Controlled, Randomized, Double-blind, Clinical Trial Completed NCT00847080 Phase 4 Sitagliptin phosphate;Placebo
9 Effect of Lixisenatide on Glucagon Secretion During Hypoglycemia in Patients With Insulin-treated Type 2 Diabetes Completed NCT02020629 Phase 4 Lixisenatide
10 Target Glycemic Control and the Incidence of Documented Symptomatic Hypoglycemia in Insulin naïve Subjects With Type 2 Diabetes Failing on Oral Hypoglycemic Agent(s) and Treated With Insulin Glargine or Insulin Detemir. Completed NCT00405418 Phase 4 Insulin glargine;Insulin Detemir
11 The Incidence of Hypoglycemia in Insulin Glargine-Treated Subjects With Diabetes Mellitus Upon Switching Between Bedtime and Morning Dosing Completed NCT00609895 Phase 4 INSULIN GLARGINE
12 An Open-Label, Randomized Naturalistic Study to Evaluate the Incidence of Hypoglycemia Comparing Sitagliptin With Sulfonylurea Treatment in Patients With Type 2 Diabetes During Ramadan Fasting Completed NCT01131182 Phase 4 Sitagliptin phosphate;Comparator: Sulfonylurea;Metformin
13 Study of the Effect of Vildagliptin on Glucagon Counterregulation Response During Hypoglycemia in Patients With Type 1 Diabetes Completed NCT01147276 Phase 4 Vildagliptin
14 Treatment of Hypoglycemia Following Gastric Bypass Surgery Completed NCT02527993 Phase 4 Glucobay (acarbose);Januvia (sitagliptin);Verapamil HEXAL (verapamil);Victoza (liraglutide);Signifor (pasireotide)
15 A Multicenter, Prospective, Randomized, Open-label, Parallel Group Study to Investigate the Clinical Benefit on Hypoglycemia Frequency of 24 Weeks Treatment With Galvus Versus Usual Care (Any OAD of Another Class Added to Metformin Within SmPc) in Older Patients With Type 2 Diabetes Insufficiently Controlled by Metformin Monotherapy. Completed NCT01238978 Phase 4 Vildagliptin;"Usual Care"
16 Study of the Effect of Vildagliptin on Glucagon Counterregulation Response During Hypoglycemia in Insulin-treated Patients With Type 2 Diabetes Completed NCT01219400 Phase 4 Vildagliptin
17 Glycemic Excursions in Type 2 Diabetic Patients Treated With Vildagliptin and Metformin (GalvusMet) Versus Glimepiride and Metformin Completed NCT02007278 Phase 4 vildagliptin and metformin (combination);glimepiride;Metformin
18 Bedtime Insulin Glargine or Bedtime Neutral Protamine Lispro Combined With Sulfonylurea and Metformin in Type 2 Diabetes. A Randomized, Controlled Trial Completed NCT00641407 Phase 4 NPL insulin;Insulin glargine
19 Randomized, Double-blind, Placebo-controlled Crossover Trial Assessing the Impact of the SGLT2 Inhibitor Empagliflozin on Postprandial Hypoglycaemia After Gastric Bypass Completed NCT05057819 Phase 4 Empagliflozin 25 MG;Placebo
20 Glucagon Efficiency After High and Low Carbohydrate Diet Completed NCT02578498 Phase 4
21 The Effect of Glucomannan Soluble Fiber on Glucose Homeostasis in Patients With RNY Gastric Bypass Surgery Completed NCT02336438 Phase 4
22 Phase IV Study to Compare the Accuracy and Precission of Five Different Home Glucose Monitors;Optium Xceed, Contour Ts, Accu-chek Go, One Touch Select and Ez Smart Completed NCT01013402 Phase 4 Human insulin;Human Insulin
23 Dual-hormone Closed-loop Glucose Control in Type 1 Diabetes Completed NCT04053712 Phase 4 Glucagon
24 Effect of Ciprofloxacin Versus Levofloxacin on QTc-interval and Dysglycemia in Diabetic and Non-Diabetic Patients. Completed NCT04456712 Phase 4 Ciprofloxacin 400 MG/200 ML Intravenous Solution;Levofloxacin 750 MG
25 The Effect of Insulin Degludec on Risk of Symptomatic Nocturnal Hypoglycaemia in Subjects With Type 1 Diabetes and High Risk of Nocturnal Severe Hypoglycaemia Completed NCT02192450 Phase 4 Insulin aspart/glargine;Insulin aspart/degludec
26 The Late Effects of Ethanol Intake on the Glucose Response to Subcutaneous Glucagon in Type 1 Diabetes Completed NCT02881060 Phase 4
27 A Phase IIIb/IV, Multinational, Multicentre, Randomised, Open Study to Establish the Optimal Method for Initiating and Maintaining Lantus® (Insulin Glargine) Therapy Based on a Comparison of Two Treatment Algorithms to Determine Optimal Metabolic Outcomes, Safety, and Satisfaction in Subjects With Type 1 Diabetes Mellitus/ "HALT" Sub-study: Multicentre, Open Clinical Trial to Assess the Effect of Insulin Glargine on Symptomatic Hypoglycaemia, Fear of Hypoglycaemia and Quality of Life in Patients With Type 1 Diabetes Completed NCT00390728 Phase 4 Insulin Glargine
28 Can Hypoglycaemia Awareness Be Restored in Individuals With Type 1 Diabetes and Severe Hypoglycaemia Employing Optimised Subcutaneous Insulin Regime or Continuous Subcutaneous Insulin Infusion Pump Completed NCT00360984 Phase 4 insulin glargine
29 The Effect of Insulin Analogues and Human Insulin on the Incidence of Severe Hypoglycaemia in Hypoglycaemia Prone Type 1 Diabetic Patients Completed NCT00346996 Phase 4 insulin levemir / aspart;human insulin /insulin isophane
30 Use of Diazoxide in Acute Hypoglycaemia Completed NCT01488136 Phase 4 Diazoxide;Placebo
31 A Double-blind, Randomised, Crossover Study to Investigate the Difference in Frequency of Episodes of Hypoglycaemia During Treatment With Biphasic Insulin Aspart 30 Compared to Biphasic Human Insulin 30 in Patients With Well-controlled Type 2 Diabetes Completed NCT01487798 Phase 4 biphasic human insulin 30;biphasic insulin aspart 30
32 A Randomised, Parallel-group, Open-label, Multinational Trial Comparing the Safety and Efficacy of Insulin Aspart (NovoRapid®) Versus Human Insulin (Actrapid®), Used in a Multiple Injection Regimen, in the Treatment of Pregnant Women With Type 1 Diabetes, Focusing on Maternal Hypoglycaemia and Pregnancy Outcomes Completed NCT00365170 Phase 4 human insulin;insulin aspart
33 Liraglutide in Type 1 Diabetes. A Randomised, Double-blind, Placebo Controlled Study of the Effect of Liraglutide as an Additional Treatment to Insulin on HbA1c, Body Weight and Hypoglycaemia in Poorly Regulated Type 1 Diabetes Patients Completed NCT01612468 Phase 4 Liraglutide;Placebo
34 The Effect of Long- and Intermediate-acting Insulins on Glycemic Control and Risk of Hypoglycemia Among Toddlers and Preschool Children With Newly Onset Type 1 Diabetes Mellitus: A Randomized Three Armed Trial Recruiting NCT04664764 Phase 4 Degludec;Glargine;NPH insulin
35 The Effect of Metformin in Pregnant Women Who Received Antenatal Corticosteroids on Glycemic Control and the Rate of Neonatal Hypoglycemia - Multicenter Prospective Randomized, Controlled Trial Recruiting NCT04332393 Phase 4 Metformin
36 A Randomized Cross-over Trial Evaluating Automated Insulin Delivery Technologies on Hypoglycemia and Quality of Life in Elderly Adults With Type 1 Diabetes Recruiting NCT04016662 Phase 4
37 Difference of Basal Insulin Titration Method in Reducing HbA1c Among Type 2 Diabetes Mellitus (T2DM) Patients. Recruiting NCT05331469 Phase 4 NPH basal insulin titration
38 Hypoglycemia and Autonomic Nervous System Function Active, not recruiting NCT03429946 Phase 4 Spironolactone;Placebo
39 Timing of Late Preterm Corticosteroid Administration and Neonatal Hypoglycemia Not yet recruiting NCT04869709 Phase 4 Betamethasone Sodium Phosphate
40 Novel Approach for the Prevention of Hypoglycemia Associated Autonomic Failure (HAAF) Suspended NCT03608163 Phase 4 Naloxone;Diazoxide;Placebo (for Naloxone);Placebo (for Diazoxide)
41 Effects of Insulin Detemir Versus Regular Insulin (Actrapid) on Hormonal Counterregulation, Cognitive Function and Symptom Perception During Hypoglycemia Terminated NCT00490893 Phase 4 Detemir
42 Randomized Double Blind Parallel Design Study Comparing Risk of Nocturnal Hypoglycemia and Critical Arrhythmia With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes Insufficiently Controlled With Metformin Monotherapy Terminated NCT02373865 Phase 4 Sitagliptin;Glimepiride;Sitagliptin-Placebo;Glimepiride-Placebo
43 Comparison of Neutral Protamine Hagedorn (NPH) and Lantus Based Insulin Regimen in the Management of Hypoglycemia in the Hospitalized Patients in Noncritical Care Setting Terminated NCT02189395 Phase 4 NPH and regular insulin;glargine and humalog
44 Sitagliptin Versus Sulphonylurea Based Treatments in Muslim Patients With Type 2 Diabetes During Ramadan Terminated NCT00766441 Phase 4 Sitagliptin;sulphonylurea
45 Comparison of Two Strategies of Hypoglycemia Correction in ICU Withdrawn NCT01387477 Phase 4 Lactate;Glucose
46 Use for Diazoxide in the Initial Management of Hypoglycemia in Infants of Diabetic Mothers and Infants Large for Gestation Unknown status NCT00994149 Phase 2, Phase 3 Diazoxide;Ora-plus
47 To Examine if the Mother's Glucose Levels and Glucose Levels in the Blood Can Predict Cord Hypoglycemia in Newborns at Risk. Unknown status NCT02838875 Phase 3
48 G-Pen (Glucagon Injection) Compared to GlucaGen® Hypokit® (Glucagon) for Induced Hypoglycemia Rescue in Adults With T1D: A Phase 3 Multi-center, Randomized, Controlled, Single Blind, 2-way Crossover Study to Evaluate Efficacy and Safety Completed NCT03738865 Phase 3 G-Pen;Novo Glucagon
49 G-Pen™ (Glucagon Injection) Compared to Lilly Glucagon (Glucagon for Injection [RDNA Origin]) for Induced Hypoglycemia Rescue in Adults With T1D: a Phase 3 B Multi-Centered, Randomized, Controlled, Single Blind, 2-Way Crossover Study to Evaluate Efficacy and Safety Completed NCT03439072 Phase 3 G-Pen;Lilly Glucagon
50 A Randomized, Double-blind, Parallel-group Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Rescue Treatment of Hypoglycemia in Subjects With Type 1 Diabetes Mellitus (T1DM) Compared to Placebo Completed NCT03688711 Phase 3 Dasiglucagon;Placebo

Search NIH Clinical Center for Hypoglycemia

Inferred drug relations via UMLS 71 / NDF-RT 50 :


DEXTROSE 100% PWDR
Diazoxide
Glucagon
Glucose
GLUCOSE LIQUID

Cochrane evidence based reviews: hypoglycemia

Genetic Tests for Hypoglycemia

Genetic tests related to Hypoglycemia:

# Genetic test Affiliating Genes
1 Hypoglycemia 28

Anatomical Context for Hypoglycemia

Organs/tissues related to Hypoglycemia:

MalaCards : Liver, Kidney, Heart, Brain, Pancreas, Pancreatic Islet, Pituitary

Publications for Hypoglycemia

Articles related to Hypoglycemia:

(show top 50) (show all 41568)
# Title Authors PMID Year
1
Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog®) in Patients with Type 1 Diabetes After 24 Weeks: A Randomized Open-Label Study. 62 41
36114990 2022
2
Neurocognitive Outcomes at Age 2 Years After Neonatal Hypoglycemia in a Cohort of Participants From the hPOD Randomized Trial. 62 41
36219444 2022
3
Impact of tight glycemic control and hypoglycemia after pediatric cardiac surgery on neurodevelopmental outcomes at three years of age: Findings from a randomized clinical trial. 62 41
36071424 2022
4
IGF2 over-expression in solitary fibrous tumours is independent of anatomical location and is related to loss of imprinting. 53 62
20527023 2010
5
Prolonged survival and improved glycemia in BioBreeding diabetic rats after early sustained exposure to glucagon-like peptide 1. 53 62
20527046 2010
6
[A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)]. 53 62
20519186 2010
7
Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors. 53 62
20463416 2010
8
Diazoxide-responsive hyperinsulinemic hypoglycemia caused by HNF4A gene mutations. 53 62
20164212 2010
9
Prevention of nocturnal hypoglycemia using predictive alarm algorithms and insulin pump suspension. 53 62
20200307 2010
10
Glucose transporter type 1 deficiency: ketogenic diet in three patients with atypical phenotype. 53 62
19515520 2010
11
Transient salt wasting in POMC-deficiency due to infection induced stress. 53 62
19998238 2010
12
Brain glucosamine boosts protective glucoprivic feeding. 53 62
20179264 2010
13
A case of a giant phyllodes tumor of the breast with hypoglycemia caused by high-molecular-weight insulin-like growth factor II. 53 62
19259766 2010
14
Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. 53 62
20380655 2010
15
Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function. 53 62
20206728 2010
16
Solitary fibrous tumor of soft tissue: a case report and immunohistochemical study. 53 62
20340008 2010
17
Type B insulin resistance syndrome with systemic lupus erythematosus. 53 62
20129024 2010
18
Therapeutic options that provide glycemic control and weight loss for patients with type 2 diabetes. 53 62
20107301 2010
19
Hypoglycemia due to ectopic secretion of insulin-like growth factor-I in a patient with an isolated sarcoidosis of the spleen. 53 62
20081321 2010
20
A novel mutation in the glycogen synthase 2 gene in a child with glycogen storage disease type 0. 53 62
20051115 2010
21
[Late onset 3-HMG-CoA lyase deficiency: a rare but treatable disorder]. 53 62
19932602 2010
22
Reaching HbA1c goals with saxagliptin in combination with other oral antidiabetic drugs. 53 62
20107298 2010
23
In vivo phosphoenolpyruvate carboxykinase promoter mapping identifies disrupted hormonal synergism as a target of inflammation during sepsis in mice. 53 62
19821526 2009
24
Novel FBP1 gene mutations in Arab patients with fructose-1,6-bisphosphatase deficiency. 53 62
19259699 2009
25
Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. 53 62
19790256 2009
26
Treatment of type 1 diabetic patients with glucagon-like peptide-1 (GLP-1) and GLP-1R agonists. 53 62
19925391 2009
27
Differential effects of insulin detemir and neutral protamine Hagedorn (NPH) insulin on hepatic glucose production and peripheral glucose uptake during hypoglycaemia in type 1 diabetes. 53 62
19707744 2009
28
Hyperinsulinaemic hypoglycaemia associated with a heterozygous missense mutation of R1174W in the insulin receptor (IR) gene. 53 62
19170714 2009
29
DPP-4 inhibitors in clinical practice. 53 62
19940419 2009
30
Malignant solitary fibrous tumor: report of 3 cases with unusual features. 53 62
19349855 2009
31
New therapies for diabesity. 53 62
19793506 2009
32
Treatment of dwarfism with recombinant human insulin-like growth factor-1. 53 62
19946434 2009
33
No increased risk of hypoglycaemic episodes during 48 h of subcutaneous glucagon-like-peptide-1 administration in fasting healthy subjects. 53 62
19094067 2009
34
Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus. 53 62
19638470 2009
35
Selecting among ADA/EASD tier 1 and tier 2 treatment options. 53 62
19744422 2009
36
Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. 53 62
19801361 2009
37
Beta-human chorionic gonadotropin production associated with phyllodes tumor of the breast: an unusual paraneoplastic phenomenon. 53 62
19624411 2009
38
Defining the importance of daily glycemic control and implications for type 2 diabetes management. 53 62
19820277 2009
39
Hypoglycemia with intensive insulin therapy in critically ill patients: predisposing factors and association with mortality. 53 62
19623047 2009
40
[Diagnosis of glycogen storage disease type IIIA by detecting glycogen debranching enzyme activity, glycogen content and structure in muscle]. 53 62
19951495 2009
41
Short-term effects of the long-acting insulin analog detemir and human insulin on plasma levels of insulin-like growth factor-I and its binding proteins in humans. 53 62
19470629 2009
42
Hemangiopericytoma-associated hypoglycemia improved by glucocorticoid therapy: a case report. 53 62
19387873 2009
43
Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists. 53 62
19624785 2009
44
Hypoglycemia from IGF2 overexpression associated with activation of fetal promoters and loss of imprinting in a metastatic hemangiopericytoma. 53 62
19383775 2009
45
[A case of retroperitoneal solitary fibrous tumor associated with hypoglycemia]. 53 62
19673425 2009
46
3-Hydroxyacyl-coenzyme A dehydrogenase deficiency and hyperinsulinemic hypoglycemia: characterization of a novel mutation and severe dietary protein sensitivity. 53 62
19417036 2009
47
Lys169 of human glucokinase is a determinant for glucose phosphorylation: implication for the atomic mechanism of glucokinase catalysis. 53 62
19617908 2009
48
Expression of insulin-like growth factor 2 in mesenchymal neoplasms. 53 62
19407853 2009
49
Factors determining inadequate hypoglycaemia during insulin tolerance testing (ITT) after pituitary surgery. 53 62
19178524 2009
50
Delay in blood glucose monitoring during an insulin infusion protocol is associated with increased risk of hypoglycemia in intensive care units. 53 62
19670374 2009

Variations for Hypoglycemia

ClinVar genetic disease variations for Hypoglycemia:

5 (show all 11)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 KCNJ11 NM_000525.4(KCNJ11):c.617G>T (p.Arg206Leu) SNV Likely Risk Allele
556175 rs1554901747 GRCh37: 11:17409022-17409022
GRCh38: 11:17387475-17387475
2 KCNJ11 NM_000525.4(KCNJ11):c.466G>A (p.Gly156Arg) SNV Likely Risk Allele
8684 rs1404429785 GRCh37: 11:17409173-17409173
GRCh38: 11:17387626-17387626
3 G6PC1 NM_000151.4(G6PC1):c.247C>T (p.Arg83Cys) SNV Pathogenic
11998 rs1801175 GRCh37: 17:41055964-41055964
GRCh38: 17:42903947-42903947
4 ABCC8 NM_000352.6(ABCC8):c.3753+1G>A SNV Pathogenic
552226 rs1554906786 GRCh37: 11:17419885-17419885
GRCh38: 11:17398338-17398338
5 ABCC8 NM_000352.6(ABCC8):c.3517G>A (p.Val1173Met) SNV Likely Pathogenic
35609 rs141322087 GRCh37: 11:17426099-17426099
GRCh38: 11:17404552-17404552
6 ABCC8 NM_000352.6(ABCC8):c.1793G>A (p.Arg598Gln) SNV Likely Pathogenic
523361 rs1344172059 GRCh37: 11:17452385-17452385
GRCh38: 11:17430838-17430838
7 ABCC8 NM_000352.6(ABCC8):c.1024G>T (p.Gly342Trp) SNV Likely Pathogenic
523360 rs763028380 GRCh37: 11:17474818-17474818
GRCh38: 11:17453271-17453271
8 KCNJ11 NM_000525.4(KCNJ11):c.185C>G (p.Thr62Arg) SNV Likely Pathogenic
373928 rs1057518775 GRCh37: 11:17409454-17409454
GRCh38: 11:17387907-17387907
9 MYOM1 NM_003803.4(MYOM1):c.3260G>A (p.Trp1087Ter) SNV Likely Pathogenic
804425 rs374670754 GRCh37: 18:3116372-3116372
GRCh38: 18:3116374-3116374
10 MYO7A NM_000260.4(MYO7A):c.3833C>T (p.Thr1278Ile) SNV Uncertain Significance
1683776 GRCh37: 11:76901824-76901824
GRCh38: 11:77190779-77190779
11 SCN1A-AS1, SCN9A NM_001365536.1(SCN9A):c.1997A>G (p.Lys666Arg) SNV Uncertain Significance
6367 rs121908919 GRCh37: 2:167138296-167138296
GRCh38: 2:166281786-166281786

Expression for Hypoglycemia

Search GEO for disease gene expression data for Hypoglycemia.

Pathways for Hypoglycemia



Pathways directly related to Hypoglycemia:

# Pathway Source
1 Defective ABCC8 can cause hypo- and hyper-glycemias Reactome 66

Pathways related to Hypoglycemia according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.34 SLC25A20 SLC16A1 KCNJ11 INS HADH GYS2
2
Show member pathways
12.79 INSR INS IGF2 GYS2 G6PC1
3
Show member pathways
12.72 GYS2 GCK G6PC1 FBP1 AGL
4
Show member pathways
12.64 SLC25A20 HADH CPT1A ACADVL ACADM ACADL
5
Show member pathways
12.36 INSR GYS2 G6PC1 FBP1
6
Show member pathways
12.33 KCNJ11 INS GCG ABCC8
7 12.33 INSR INS GLUD1 GCG FBP1 CPT1A
8
Show member pathways
12.28 SLC16A1 KCNJ11 GCK ABCC8
9
Show member pathways
12.03 INSR INS GYS2 CPT1A
10 12 GCK G6PC1 CPT1A ACADM
11
Show member pathways
11.94 INSR INS GYS2 CPT1A
12
Show member pathways
11.87 INSR INS GCK
13
Show member pathways
11.82 SLC25A20 GCG CPT1A
14
Show member pathways
11.71 ACADM GLUD1 HADH
15
Show member pathways
11.66 ACADL ACADM ACADVL HADH
16
Show member pathways
11.64 CPT1A ACADM ACADL
17 11.42 KCNJ11 GYS2 CPT1A ABCC8
18
Show member pathways
11.23 ACADL ACADM ACADVL CPT1A HADH SLC25A20
19
Show member pathways
11.17 GYS2 GCK G6PC1 AGL
20 11.1 KCNJ11 INSR INS GCK ABCC8
21 10.88 INSR INS
22
Show member pathways
10.86 KCNJ11 INS HADH GCK G6PC1 ACADVL

GO Terms for Hypoglycemia

Cellular components related to Hypoglycemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mitochondrion GO:0005739 9.91 SLC25A20 HADH GLUD1 GCK CPT1A ACADVL
2 inward rectifying potassium channel GO:0008282 8.92 KCNJ11 ABCC8

Biological processes related to Hypoglycemia according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 lipid metabolic process GO:0006629 10.11 ACADL ACADM ACADVL CPT1A HADH SLC16A1
2 insulin receptor signaling pathway GO:0008286 10.09 INSR INS IGF2
3 fatty acid beta-oxidation GO:0006635 10.03 HADH CPT1A ACADM
4 gluconeogenesis GO:0006094 10.02 GCG G6PC1 FBP1
5 negative regulation of insulin secretion GO:0046676 9.99 KCNJ11 HADH ABCC8
6 glucose metabolic process GO:0006006 9.96 CPT1A GCK IGF2 INS KCNJ11
7 positive regulation of mitotic nuclear division GO:0045840 9.95 IGF2 INS INSR
8 glucose homeostasis GO:0042593 9.93 SLC16A1 INSR INS GCK GCG G6PC1
9 glucose 6-phosphate metabolic process GO:0051156 9.91 GCK G6PC1
10 glycogen catabolic process GO:0005980 9.91 G6PC1 AGL
11 glycogen biosynthetic process GO:0005978 9.91 GYS2 AGL ACADM
12 negative regulation of fatty acid oxidation GO:0046322 9.9 ACADVL ACADL
13 positive regulation of respiratory burst GO:0060267 9.88 INSR INS
14 exocrine pancreas development GO:0031017 9.88 INSR IGF2
15 fatty acid metabolic process GO:0006631 9.88 HADH CPT1A ACADVL ACADM ACADL
16 carbohydrate metabolic process GO:0005975 9.87 INSR INS IGF2 GCK FBP1 AGL
17 fatty acid beta-oxidation using acyl-CoA dehydrogenase GO:0033539 9.85 ACADVL ACADM ACADL
18 carnitine shuttle GO:0006853 9.84 SLC25A20 CPT1A
19 metabolic process GO:0008152 9.83 GYS2 GCK FBP1 AGL
20 positive regulation of insulin secretion involved in cellular response to glucose stimulus GO:0035774 9.8 ABCC8 GCG KCNJ11
21 carnitine metabolic process GO:0009437 9.77 CPT1A ACADM
22 carnitine metabolic process, CoA-linked GO:0019254 9.76 ACADM ACADL
23 positive regulation of glycogen biosynthetic process GO:0045725 9.56 INSR INS IGF2 GCK
24 regulation of insulin secretion GO:0050796 9.4 SLC16A1 KCNJ11 HADH GCK GCG CPT1A

Molecular functions related to Hypoglycemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 10.37 ACADL ACADM ACADVL CPT1A FBP1 GCG
2 flavin adenine dinucleotide binding GO:0050660 9.91 ACADVL ACADM ACADL
3 hormone activity GO:0005179 9.86 INS IGF2 GCG CRH
4 ATP-activated inward rectifier potassium channel activity GO:0015272 9.71 KCNJ11 ABCC8
5 long-chain-acyl-CoA dehydrogenase activity GO:0004466 9.62 ACADVL ACADL
6 insulin-like growth factor receptor binding GO:0005159 9.43 INSR INS IGF2
7 oxidoreductase activity, acting on the CH-CH group of donors GO:0016627 9.33 ACADVL ACADM ACADL
8 acyl-CoA dehydrogenase activity GO:0003995 9.1 ACADVL ACADM ACADL

Sources for Hypoglycemia

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....